Rob van Maanen

943 total citations
19 papers, 498 citations indexed

About

Rob van Maanen is a scholar working on Urology, Rheumatology and Epidemiology. According to data from OpenAlex, Rob van Maanen has authored 19 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Urology, 8 papers in Rheumatology and 7 papers in Epidemiology. Recurrent topics in Rob van Maanen's work include Urinary Bladder and Prostate Research (10 papers), Pelvic floor disorders treatments (8 papers) and Urinary Tract Infections Management (5 papers). Rob van Maanen is often cited by papers focused on Urinary Bladder and Prostate Research (10 papers), Pelvic floor disorders treatments (8 papers) and Urinary Tract Infections Management (5 papers). Rob van Maanen collaborates with scholars based in United States, Netherlands and United Kingdom. Rob van Maanen's co-authors include Asha Paireddy, Arwin Ridder, Paul Abrams, Tomasz Rechberger, David Staskin, Dudley Robinson, Matthias Stoelzel, Reynaldo Martina, Donald Newgreen and Con Kelleher and has published in prestigious journals such as SHILAP Revista de lepidopterología, Brain and Clinical Infectious Diseases.

In The Last Decade

Rob van Maanen

18 papers receiving 488 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rob van Maanen United States	8	395	312	287	88	49	19	498
Vasudha Vats United States	9	539 1.4×	511 1.6×	279 1.0×	102 1.2×	2 0.0×	9	629
Sara Y. Gao United States	6	294 0.7×	176 0.6×	134 0.5×	57 0.6×	2 0.0×	11	350
Karen Irvine‐Bird Canada	9	297 0.8×	207 0.7×	164 0.6×	44 0.5×		10	400
Metin Onaran Türkiye	12	142 0.4×	103 0.3×	34 0.1×	84 1.0×	2 0.0×	28	358
Osamu Natsume Japan	8	68 0.2×	51 0.2×	50 0.2×	152 1.7×	3 0.1×	39	452
Hans Thyssen Denmark	10	111 0.3×	220 0.7×	85 0.3×	124 1.4×	2 0.0×	15	323
Canan Ceran Türkiye	8	45 0.1×	31 0.1×	20 0.1×	177 2.0×	5 0.1×	24	284
C Grytter Denmark	9	44 0.1×	25 0.1×	134 0.5×	78 0.9×	3 0.1×	13	442
Louise A Beveridge United Kingdom	4	24 0.1×	25 0.1×	66 0.2×	52 0.6×	3 0.1×	4	197
David Dvir Israel	4	32 0.1×	7 0.0×	27 0.1×	66 0.8×	28 0.6×	13	417

Countries citing papers authored by Rob van Maanen

Since Specialization

Citations

This map shows the geographic impact of Rob van Maanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob van Maanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob van Maanen more than expected).

Fields of papers citing papers by Rob van Maanen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rob van Maanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob van Maanen. The network helps show where Rob van Maanen may publish in the future.

Co-authorship network of co-authors of Rob van Maanen

This figure shows the co-authorship network connecting the top 25 collaborators of Rob van Maanen. A scholar is included among the top collaborators of Rob van Maanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rob van Maanen. Rob van Maanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Camelo, Serge, Waly Dioh, J. Pedro Teixeira, et al.. (2025). Modulation of the renin-angiotensin system against COVID-19: A path forward?. International Journal of Infectious Diseases. 154. 107867–107867.

Fielding, Roger A., Yves Rolland, Olivier Bruyère, et al.. (2025). Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS). BMC Geriatrics. 25(1). 590–590. 1 indexed citations

Smeıtınk, Jan, Jan van Es, Mirian C. H. Janssen, et al.. (2024). Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation. Brain. 148(3). 896–907. 3 indexed citations

Dioh, Waly, Vihang A. Narkar, Anurag Singh, et al.. (2023). Novel Potential Targets for Function-Promoting Therapies: Orphan Nuclear Receptors, Anti-inflammatory Drugs, Troponin Activators, Mas Receptor Agonists, and Urolithin A. The Journals of Gerontology Series A. 78(Supplement_1). 44–52. 1 indexed citations

Smeıtınk, Jan, et al.. (2022). A randomised placebo-controlled, double-blind phase II study to explore the safety, efficacy, and pharmacokinetics of sonlicromanol in children with genetically confirmed mitochondrial disease and motor symptoms (“KHENERGYC”). BMC Neurology. 22(1). 158–158. 7 indexed citations

Choudhury, Nurul, et al.. (2021). The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study. BMC Urology. 21(1). 119–119. 5 indexed citations

Karaa, Amel, John C. Campbell, John Christodoulou, et al.. (2021). Community Consensus Guidelines to Support FAIR Data Standards in Clinical Research Studies in Primary Mitochondrial Disease. SHILAP Revista de lepidopterología. 3(1). 2 indexed citations

Gratzke, Christian, Christopher R. Chapple, Elizabeth R. Mueller, et al.. (2019). Efficacy and Safety of Combination Pharmacotherapy for Patients with Overactive Bladder: A Rapid Evidence Assessment. European Urology. 76(6). 767–779. 20 indexed citations

Wolf, Joshua, Clàudia Fortuny, Samantha Bosis, et al.. (2019). Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). Clinical Infectious Diseases. 71(10). 2581–2588. 50 indexed citations

10.

Mueller, Elizabeth R., Rob van Maanen, Christopher R. Chapple, et al.. (2019). Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study. Neurourology and Urodynamics. 38(2). 779–792. 13 indexed citations

11.

Gratzke, Christian, Rob van Maanen, Christopher R. Chapple, et al.. (2018). Long-term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). European Urology. 74(4). 501–509. 67 indexed citations

12.

Wolf, Joshua, Clàudia Fortuny, Samantha Bosis, et al.. (2018). LB12. Safety and Efficacy of Fidaxomicin and Vancomycin in Pediatric Patients with Clostridium difficile Infection: Phase III, Multicenter, Investigator-blind, Randomized, Parallel Group (SUNSHINE) Study. Open Forum Infectious Diseases. 5(suppl_1). S763–S764. 1 indexed citations

13.

Herschorn, Sender, Christopher R. Chapple, Paul Abrams, et al.. (2017). Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( SYNERGY study). British Journal of Urology. 120(4). 562–575. 108 indexed citations

14.

Gratzke, Christian, Rob van Maanen, Christopher R. Chapple, et al.. (2017). PNFLBA-09 LONG-TERM COMBINATION TREATMENT WITH SOLIFENACIN AND MIRABEGRON IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH OVERACTIVE BLADDER. The Journal of Urology. 197(4S). 1 indexed citations

15.

Robinson, Dudley, Con Kelleher, David Staskin, et al.. (2017). Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourology and Urodynamics. 37(1). 394–406. 24 indexed citations

16.

Abrams, Paul, Jean Paty, Reynaldo Martina, et al.. (2015). Electronic bladder diaries of differing duration versus a paper diary for data collection in overactive bladder. Neurourology and Urodynamics. 35(6). 743–749. 22 indexed citations

17.

Abrams, Paul, Con Kelleher, David Staskin, et al.. (2014). Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony). European Urology. 67(3). 577–588. 163 indexed citations

18.

Abrams, Paul, Con Kelleher, David Staskin, et al.. (2013). 1958 COMBINATION TREATMENT WITH MIRABEGRON AND SOLIFENACIN IN PATIENTS WITH OVERACTIVE BLADDER (OAB) - EFFICACY RESULTS FROM A PHASE 2 STUDY (SYMPHONY). The Journal of Urology. 189(4S). 6 indexed citations

19.

Maanen, Rob van & Darren Bentley. (2009). Bioequivalence of zonisamide orally dispersible tablet and immediate-release capsule formulations: Results from two open-label, randomized-sequence, single-dose, two-period, two-treatment crossover studies in healthy male volunteers. Clinical Therapeutics. 31(6). 1244–1255. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact